Hematology

Latest News

The data suggest BsAbs are safe and effective in many patients with relapsed or refractory LBCL following CAR T-cell therapy. | Image credit: jarun011 - stock.adobe.com
Early Relapse After CAR T-Cell Therapy Linked With Poor BsAb Outcomes in LBCL

May 23rd 2025

Elevated LDH and higher international prognostic index were also predictors of poor outcomes on bispecific antibodies, investigators found.

Even among patients with MDS and anemia with a high transfusion burden, 7 of 12 patients who responded experienced responses lasting longer than 6 months. | Image Credit: Eleni - stock.adobe.com
Safety, Efficacy of Luspatercept for MDS Confirmed in Real-World Setting

May 22nd 2025

Among patients in the real-world setting, acalabrutinib was associated with reduced risks of AF or flutter and a reduced risk of hypertension. | Image credit: inthasone - stock.adobe.com
Lower Risk of Cardiovascular Events With Acalabrutinib vs Ibrutinib in CLL in Real-World Study

May 17th 2025

Overall, there were 36 factors identified as having a prognostic impact on at least 1 clinical outcome. | Image Credit: laszlo - stock.adobe.com
Review Identifies Top Prognostic Factors in Third-Line or Later DLBCL

May 16th 2025

Patients with relapsed/refractory disease achieved an ORR of 63% in the phase 2 study. | Image Credit: Eleni - stock.adobe.com
Bexmarilimab Plus Azacitidine Meets ORR End Point in R/R Higher-Risk MDS

May 16th 2025

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

AJMC Peer Exchange logo

More News

Trial of Anti-BCMA ide-cel for RRMM Leads to Undetectable Disease in 33% of Patients
February 27th 2021

Trial of Anti-BCMA ide-cel for RRMM Leads to Undetectable Disease in 33% of Patients

Allison Inserro
More than 2 years after treatment, some of the patients with relapsed/refractory multiple myeloma have yet to see a relapse. An FDA decision on the therapy is expected within a month.
FDA Clears Peptide-Drug Conjugate for RRMM
February 27th 2021

FDA Clears Peptide-Drug Conjugate for RRMM

AJMC Staff
The peptide-drug conjugate rapidly delivers an alkylating payload into tumor cells.
Combination Treatment Maintains Quality of Life in Relapsed/Refractory MM
February 20th 2021

Combination Treatment Maintains Quality of Life in Relapsed/Refractory MM

Larry Hanover
Health-related quality of life was maintained when treating relapsed/refractory multiple myeloma (RRMM) with daratumumab in combination with bortezomib and dexamethasone.
Blood Cells
February 16th 2021

Sustained MRD Negativity Predictive of Long-term Outcomes in RRMM

Rose McNulty
Sustained minimal residual disease (MRD) negativity may predict long-term outcomes in relapsed/refractory multiple myeloma (RRMM), and daratumumab-based combinations show higher rates of sustained MRD negativity compared with the standard of care.
Blood
February 12th 2021

Carfilzomib Improves Renal Response Compared With Bortezomib in RRMM

Rose McNulty
Carfilzomib-dexamethasone improved renal overall and complete response in patients with relapsed or refractory multiple myeloma (RRMM) compared with a regimen of bortezomib-dexamethasone in a real-world study.
Robert K. Massie, Jr, PhD, MA, Society for Progress
February 10th 2021

Dr Robert Massie: Patient Needs Matter for Quality of Life to Not Suffer

Whereas patient care was often bogged down in bureaucracy when he was younger, Robert K. Massie Jr, PhD, MA, of the Society for Progress, notes that hospitals and caregivers are increasingly paying attention to what makes sense for patient care.
Email being sent
February 10th 2021

What We’re Reading: EUA for Lilly’s Combination Treatment; COVID-19 Billing Waivers; Convalescent Plasma Indication Updated

AJMC Staff
The FDA issues an emergency use authorization (EUA) for Eli Lilly’s coronavirus disease 2019 (COVID-19) treatment; insurance waivers for COVID-19–related costs are starting to expire; new data update convalescent plasma’s indication.
All of the panelists for this series
February 10th 2021

The Future of R/R Multiple Myeloma Management

Experts in the management of multiple myeloma consider promising developments for the future of relapsed/refractory treatment, with special consideration to bispecific antibodies and CAR (chimeric antigen receptor) T-cell therapy.
Socioeconomics
February 6th 2021

Socioeconomic Status May Determine Patient Survival From Multiple Myeloma

Larry Hanover
Patients’ socioeconomic status is a significant factor in predicting survival rates for multiple myeloma, according to a new study.
All of the panelists for this series
February 3rd 2021

The Role of Venetoclax in R/R Multiple Myeloma

Key opinion leaders consider the role of venetoclax in managing patients with relapsed/refractory multiple myeloma.
All of the panelists for this series
February 3rd 2021

Implications of the IKEMA Interim Analysis

Expert physicians consider the practical implications of the IKEMA interim analysis of isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed/refractory multiple myeloma.
Preclinical Study of Gene Therapy Vector for SCD, Beta-Thalassemia Shows Promise
January 30th 2021

Preclinical Study of Gene Therapy Vector for SCD, Beta-Thalassemia Shows Promise

AJMC Staff
An engineered lentivirus was created to avoid some of the drawbacks associated with current gene therapy vectors for sickle cell disease (SCD) and beta-thalassemia.
All of the panelists for this series
January 27th 2021

Impact of the Phase 3 APOLLO Trial Recent Findings

Key opinion leaders provide an overview of the recent findings from the APOLLO phase 3 study, and consider whether the findings have impacted their treatment algorithm in regards to potential for earlier response.
All of the panelists for this series
January 27th 2021

ASH 2020 Data: DKd Versus DVd Implications

A discussion on the practical implication of the data from the ASH (American Society of Hematology) 2020 Annual Meeting regarding DKd versus DVd.
Mark Wildgust, PhD, Janssen
January 25th 2021

Dr Mark Wildgust: Daratumumab Critical to Improving Patient Response

Daratumumab represents an important addition to the armamentarium of care for improving patient outcomes, said Mark Wildgust, PhD, vice president of Global Medical Affairs/Oncology at Janssen.
Bone marrow transplant
January 20th 2021

Higher Mortality Seen Among HSCT Recipients Who Contract COVID-19

Maggie L. Shaw
Recipients of hematopoietic stem-cell transplantation (HSCT) who develop coronavirus disease 2019 (COVID-19) may be predisposed to a greater mortality rate if they meet certain disease criteria.
ASH 2020: COVID-19 and Hematology
January 20th 2021

ASH 2020: COVID-19 and Hematology

Mary Caffrey Rose McNulty
Anthony Fauci gave his insight on the coronavirus disease 2019 (COVID-19) for immunocompromised populations at ASH 2020, and leading organizations released fact sheets and recommendations.
All of the panelists for this series
January 20th 2021

Therapy Selection for Newly Diagnosed Multiple Myeloma

Experts in the management of multiple myeloma discuss treatment selection for newly diagnosed patients, with consideration of the ENDURANCE trial and its shortcomings.
All of the panelists for this series
January 20th 2021

Clinical Significance of DKd Dosing Flexibility

Key opinion leaders discuss the clinical significance of dosing flexibility for the CANDOR trial regimen, as studied in the EQUULEUS trial.
Tube of plasma
January 14th 2021

High-Antibody Convalescent Plasma Associated With Lower Mortality Among Patients With COVID-19

Maggie L. Shaw
A comparison of 3 levels of SARS-CoV-2 antibodies in convalescent plasma shows that the 30-day death rate was lowest in the group receiving high-titer plasma.
All of the panelists for this series
January 13th 2021

CANDOR Trial Overview and Regimen Complications

An overview of the data from the CANDOR trial presented at the ASH (American Society of Hematology) 2020 annual meeting and discussion on how to manage various complications from the trial regimen.
All of the panelists for this series
January 13th 2021

Upfront Daratumumab Impact on Relapse Treatment

Key opinion leaders consider how the approval of daratumumab in the upfront setting for patients with relapsed multiple myeloma has impacted treatment strategies.
Blood cells
January 12th 2021

Natural Killer Cells Could Play Key Role in Fight Against MM

Jared Kaltwasser
Emerging research into natural killer cells has shown promise, but the findings are complicated by the heterogeneity of multiple myeloma (MM).
Stethoscope on laptop
January 7th 2021

Risk Factors for Increased Mortality Among Patients With MM, COVID-19 Identified

Maggie L. Shaw
Age, renal disease, and suboptimal myeloma control were among the many factors identified in a recent study as increasing the risk of death from coronavirus disease 2019 (COVID-19) for patients being treated for multiple myeloma (MM).
All of the panelists for this series
January 6th 2021

Treating Biochemical Relapses in Multiple Myeloma

Expert physicians provide insight into their strategy for treating biochemical relapse in patients with multiple myeloma.
All of the panelists for this series
January 6th 2021

Importance of MRD Negativity in Changing Relapse Patterns

A discussion on the importance of MRD (minimum residual disease) negativity in changing relapse patterns for patients with multiple myeloma.
Robert K. Massie, Jr, PhD, MA, Society for Progress
January 5th 2021

Dr Robert Massie: Untreated Pooled Plasma Enabled Unchecked Virus Transmission

Decades ago, companies refused to heat-treat their blood products, which resulted in pooled plasma, among others, enabling many viruses to be transmitted, noted Robert K. Massie Jr, PhD, MA, of the Society for Progress.
All of the panelists for this series
December 30th 2020

R/R Multiple Myeloma Rationale for Decreased Response

Key opinion leaders discuss why patients with multiple myeloma experience increasingly decreased response to therapy over time.
Metabolic Biomarkers Could Predict Prognosis, Treatment Outcomes in MM
December 30th 2020

Metabolic Biomarkers Could Predict Prognosis, Treatment Outcomes in MM

Jared Kaltwasser
New research shows metabolic biomarkers could be meaningful tools for predicting treatment outcomes in patients, based on a comparison of biomarkers, clinical characteristics, and therapeutic efficacy.
Top 5 Most-Read Hematology Articles for 2020
December 28th 2020

Top 5 Most-Read Hematology Articles for 2020

Mary Caffrey
Gene-editing therapy in sickle cell disease and advances in multiple myeloma dominated hematology news in 2020.
<1
...
34567891011
...
26>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo